Actor and activist Jameela Jamil has criticized tennis legend Serena Williams after the athlete appeared to promote a weight loss drug on a television show. Williams mentioned a product from the class of medications known as GLP-1 receptor agonists, commonly used for diabetes management but now widely prescribed for weight loss.

Serena Williams’ remarks quickly drew attention. Some fans expressed disappointment online, pointing out that athletes of her stature have a strong influence on public health perceptions. GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro are approved for type 2 diabetes and, in certain cases, for obesity treatment. However, experts caution that these medications are not intended for cosmetic weight loss and can have side effects including nausea, gastrointestinal issues, and in rare cases, pancreatitis.

Jameela Jamil, known for her work in body image activism, shared her concerns on social media. She argued that celebrity endorsements of weight loss drugs can normalize their casual use, potentially leading people to misuse them without medical guidance. In a follow-up post, Jamil clarified that she respects Williams but believes that the conversation about these drugs must also highlight risks, costs, and the importance of proper medical supervision.

GLP-1 receptor agonists are a class of injectable or oral medications that mimic a natural hormone called glucagon-like peptide-1. They help lower blood sugar by stimulating insulin release, slowing digestion, and reducing appetite. These drugs were originally developed for people with type 2 diabetes, but some are also approved for managing obesity in patients who meet specific medical criteria.

While they can be effective for weight loss and blood sugar control, they may cause side effects such as nausea, vomiting, constipation, and in rare cases, inflammation of the pancreas. Doctors emphasize that GLP-1 drugs should only be used under medical supervision, and they are not a substitute for healthy lifestyle habits like balanced diet and exercise.

The incident has reignited debate in the United States about the growing popularity of GLP-1 medications beyond their original medical purpose. Health experts note that while these drugs can help patients with obesity and diabetes, misuse can create both health risks and shortages for people who rely on them for chronic disease management.

Williams has not issued a detailed response to the criticism. The discussion continues online, with many highlighting the need for responsible communication about medications that affect public health.

(Rh/Eth/MSM)